These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9090335)

  • 1. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects.
    Smith GS; Dewey SL; Brodie JD; Logan J; Vitkun SA; Simkowitz P; Schloesser R; Alexoff DA; Hurley A; Cooper T; Volkow ND
    Am J Psychiatry; 1997 Apr; 154(4):490-6. PubMed ID: 9090335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective serotonin reuptake inhibitor (SSRI) modulation of striatal dopamine measured with [11C]-raclopride and positron emission tomography.
    Smith GS; Ma Y; Dhawan V; Chaly T; Eidelberg D
    Synapse; 2009 Jan; 63(1):1-6. PubMed ID: 18925655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis.
    Dewey SL; Smith GS; Logan J; Alexoff D; Ding YS; King P; Pappas N; Brodie JD; Ashby CR
    J Neurosci; 1995 Jan; 15(1 Pt 2):821-9. PubMed ID: 7823183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.
    Tiihonen J; Kuoppamäki M; Någren K; Bergman J; Eronen E; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1996 Aug; 126(4):277-80. PubMed ID: 8878342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects.
    Smith GS; Schloesser R; Brodie JD; Dewey SL; Logan J; Vitkun SA; Simkowitz P; Hurley A; Cooper T; Volkow ND; Cancro R
    Neuropsychopharmacology; 1998 Jan; 18(1):18-25. PubMed ID: 9408915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.
    Dewey SL; Smith GS; Logan J; Brodie JD; Simkowitz P; MacGregor RR; Fowler JS; Volkow ND; Wolf AP
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11816-20. PubMed ID: 8265632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels.
    Dewey SL; Smith GS; Logan J; Brodie JD; Fowler JS; Wolf AP
    Synapse; 1993 Apr; 13(4):350-6. PubMed ID: 8480281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrastriatal D2 and striatal D2 receptors in depressive illness: pilot PET studies using [11C]FLB 457 and [11C]raclopride.
    Montgomery AJ; Stokes P; Kitamura Y; Grasby PM
    J Affect Disord; 2007 Aug; 101(1-3):113-22. PubMed ID: 17197036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.
    Egerton A; Ahmad R; Hirani E; Grasby PM
    Psychopharmacology (Berl); 2008 Nov; 200(4):487-96. PubMed ID: 18597077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
    J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography.
    Dewey SL; Smith GS; Logan J; Brodie JD; Yu DW; Ferrieri RA; King PT; MacGregor RR; Martin TP; Wolf AP
    J Neurosci; 1992 Oct; 12(10):3773-80. PubMed ID: 1357114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography.
    Hume SP; Myers R; Bloomfield PM; Opacka-Juffry J; Cremer JE; Ahier RG; Luthra SK; Brooks DJ; Lammertsma AA
    Synapse; 1992 Sep; 12(1):47-54. PubMed ID: 1411963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding.
    Halldin C; Farde L; Högberg T; Hall H; Ström P; Ohlberger A; Solin O
    Int J Rad Appl Instrum B; 1991; 18(8):871-81. PubMed ID: 1839303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.
    Rinne UK; Laihinen A; Rinne JO; Någren K; Bergman J; Ruotsalainen U
    Mov Disord; 1990; 5(1):55-9. PubMed ID: 2136932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride.
    Khan N; Antonini A; Parkes D; Dahlitz MJ; Meier-Ewert K; Weindl A; Leenders KL
    Neurology; 1994 Nov; 44(11):2102-4. PubMed ID: 7969966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
    Breier A; Su TP; Saunders R; Carson RE; Kolachana BS; de Bartolomeis A; Weinberger DR; Weisenfeld N; Malhotra AK; Eckelman WC; Pickar D
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2569-74. PubMed ID: 9122236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 19. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys.
    Tsukada H; Nishiyama S; Kakiuchi T; Ohba H; Sato K; Harada N
    Brain Res; 1999 Sep; 841(1-2):160-9. PubMed ID: 10546998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.